IPS cells for modelling and treatment of human diseases / / edited by Michael J. Edel.

• TeilnehmendeR: Edel, Michael J.,
• Place / Publishing House: Basel, Switzerland : : MDPI - Multidisciplinary Digital Publishing Institute,, [2015]; ©2015
• Year of Publication: 2015
• Language: English
• Physical Description: 1 online resource (422 pages) :; illustrations
• Bibliography: Includes bibliographical references.
• Hierarchical level: Monograph
• Statement of Responsibility: edited by Michael J. Edel.

The field of reprogramming somatic cells into induced pluripotent stem cells (iPSC) has moved very quickly, from bench to bedside in just eight years since its first discovery. The best example of this is the RIKEN clinical trial this year in Japan, which will use iPSC derived retinal pigmented epithelial (RPE) cells to treat macular degeneration (MD). This is the first human disease to be tested for regeneration and repair by iPSC-derived cells and others will follow in the near future. Currently, there is an intense worldwide research effort to bring stem cell technology to the clinic for application to treat human diseases and pathologies. Human tissue diseases (including those of the lung, heart, brain, spinal cord, and muscles) drive organ bioengineering to the forefront of technology concerning cell replacement therapy. Given the critical mass of research and translational work being performed, iPSCs may very well be the cell type of choice for regenerative medicine in the future. Also, basic science questions, such as efficient differentiation protocols to the correct cell type for regenerating human tissues, the immune response of iPSC replacement therapy and genetic stability of iPSC-derived cells, are currently being investigated for future clinical applications.